RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

Diagnostic Pathology

Hany Onsy Habashy¹  Manar Ahmed Abdel-Rahman¹  Mena Mahfouz¹ 

[1] Department of Pathology, Faculty of Medicine, Mansoura University, El-Gomhoria St., Mansoura, Dakahlia, Egypt;

关键词: Breast cancer;    RRM2;    Expression;    Prognosis;   

DOI  :  10.1186/s13000-021-01174-4

来源: Springer

【 摘 要 】

BackgroundBreast cancer is one of the most common types of cancer. Ribonucleotide reductase (RNR) is a heterodimeric tetramer consisting of two Ribonucleoside-diphosphate reductase large subunits (RRM1) and two Ribonucleoside-diphosphate reductase small subunits (RRM2). RRM2 is the building subunit of RNR that is important for synthesis of Deoxynucleoside triphosphate (dNTP) during S phase of cell cycle during DNA replication. RRM2 is associated with poor prognosis in lung and colorectal cancer. In breast cancer, increased RRM2 protein level is strongly correlated with large tumour size, positive lymph node and relapse. In this study, we aimed to study expression of RRM2 in breast cancer and to correlate it with different clinicopathological parameters in Egyptian women.Material and methodsThis study was performed by investigating RRM2 protein expression in breast cancer and correlating the results with other clinicopathological variables using immunohistochemistry and tissue microarrays.ResultsAbout 77% of cases were RRM2 positive. High Ki67 was observed in cases with high RRM2 score. The majority of non-luminal cases expressed RRM2, however this was statistically insignificant. In ER positive group, RRM2 expression was associated with shorter disease free survival with borderline significance.ConclusionRRM2 protein expression can help in evaluating outcome of breast cancer patients and could be a potential therapeutic target.

【 授权许可】

CC BY